A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Trial Identifier: 6070-003
Sponsor: MSD
Collaborator:
Daiichi Sankyo
Start Date: January 2026
Primary Completion Date: November 2030
Study Completion Date: December 2030

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
China, Beijing Beijing, China, 100142
China, Shanghai Shanghai, China, 200000
China, Zhejiang Taizhou, Zhejiang, China, 317000
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Korea, Republic of, Seoul Seoul, Korea, Republic of, 06351
Korea, Republic of, Seoul Seoul, Korea, Republic of, 05505
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03080
United States, FL Orlando, FL, United States, 32806
United States, KY Edgewood, KY, United States, 41017
United States, MO St. Louis, MO, United States, 63110
United States, NJ Hackensack, NJ, United States, 07601
United States, SD Sioux Falls, SD, United States, 57105
United States, TN Knoxville, TN, United States, 37920
United States, TN Nashville, TN, United States, 37203